Top 10 Breakout Stocks You Cant Afford to Miss This Week!
The top 10 breakout stocks ready to surge this week! Get actionable insights, key levels, and expert analysis to fuel your trading strategy.
Dec 29 2024
Breakout stocks offer some of the most rewarding opportunities for traders, combining technical precision with actionable strategies. This week’s analysis highlights stocks with clear resistance levels, strong momentum, and potential for significant price movement. By staying disciplined, managing risk, and watching key levels, traders can position themselves to capitalize on these opportunities.
$BSX Boston Scientific Corporation
Boston Scientific has consistently tested its resistance at $91.45, a sign of strong buying pressure. Combined with its robust support at $88.03 and positive investor sentiment, the stock is building the momentum needed for a breakout.
Breakout above $91.45 could confirm an upward trend. Traders should consider entering near $90 with a stop-loss at $88.00, balancing risk and reward effectively.
$DELL Dell Technologies
Dell is experiencing heightened interest from institutional investors, reflected in substantial options activity. Its resistance at $138.35 provides significant upside potential, while current trading levels suggest it’s approaching a key pivot point.
Enter on a confirmed breakout above $120, targeting $138.35. Stop-loss placement at $111.96 ensures risk is controlled in case of a reversal.
$CRM Salesforce Inc.
Salesforce has been gaining attention due to its strong earnings growth and consistent performance. The stock is currently trading near $338.45, with a clear path to test its $367.87 resistance.
Traders could enter near $340 if momentum continues to build. Target $367.87 for profit-taking, with a stop-loss below $320.52 to limit downside risk.
Login to Continue Reading

Please note that the article should not be considered as investment advice or marketing, and it does not take into account the personal data and requirements of any individual. It is not a substitute for the reader's own judgment, and it should not be considered as advice or recommendation for buying or selling any securities or financial products.